Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment

Published:2024-02-12 Issue:3 Volume:21 Page:1038-1055
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Wang Tiansi¹²,Li Meichai¹²,Wei Ruting¹²,Wang Xinyu¹²,Lin Zhizhe²³,Chen Jianming¹²,Wu Xin¹²

Affiliation:

1. Fujian University of Traditional Chinese Medicine, No. 1, Qiuyang Road, Fuzhou, Fujian 350122, China

2. Shanghai Wei Er Lab, Shanghai 201799, China

3. Shandong University of Traditional Chinese Medicine, No.4655, University Road, Jinan, Shandong 250355, China

Funder

National Natural Science Foundation of China

Shanghai Science and Technology Project of Little Giant

Shanghai Qingpu District Industry-University-Research Cooperative Development Funding Project

Jiaxing Key Laboratory of Oncological Photodynamic Therapy and Targeted Drug Research

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c01049

Reference100 articles.

1. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

2. Cure of Disseminated Human Lymphoma with [²²⁵Ac]Ac-Ofatumumab in a Preclinical Model

3. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

4. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

5. A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule–Drug, Antibody–Drug, and Peptide–Drug Conjugates

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Receptor-Targeted Nanomedicine for Cancer Therapy;Receptors;2024-07-03

2. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3